Inactief instrument

Andere talen Achieve Life Sciences Inc Nasdaq

Aandelen

US68230A1060

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Achieve Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update	09/05
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine	06/05
Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine	06/05
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024	25/04
Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference	11/04
Achieve Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update	28/03
Achieve Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting	20/03
Achieve Life Sciences, Inc. Announces Data from Cytisinicline ORCA Program to Be Presented at the 2024 Society for Research on Nicotine and Tobacco Annual Meeting	20/03
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024	14/03
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences	06/03
Sector Update: Health Care Stocks Decline Late Afternoon	29/02
Sector Update: Health Care	29/02
Achieve Life Sciences Agrees on Safety Exposure Data for Smoking Cessation Medication as Part of NDA	29/02
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission	29/02
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement	29/02
Top Midday Decliners	12/12
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Achieve Life Sciences Inc Nasdaq

Aandelen

US68230A1060

Andere talen

Filters